News | April 30, 2021
Lonza and Moderna enter new agreement to double drug substance production for COVID-19 vaccine
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
New agreement for three further production lines at Lonza’s site in Visp, Switzerland
CEPI will commit up to US $50 million to fund preclinical research and Phase 1 clinical trials of Moderna’s mRNA-based vaccine candidate
New purpose-built AI model targets faster R&D cycles and deeper scientific insights across life sciences
CureVac is among many pharmaceutical companies looking to produce a novel seasonal influenza vaccine via mRNA technology
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
Pfizer is likely to show GSK significant competition
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Designation based on positive data from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial and unmet need for additional therapeutic options for certain types of melanoma
The forecast across the seven years between 2022 and 2028 saw an average decline of 7%, resulting in a $10 billion drop in the total forecast sales between 2021 and 2028
The WHO has urged China to increase adoption of mRNA vaccines, given their high efficacy against variant strains.
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
